When mRNA expression of HER2, ER and PR were applied together, the over-all accuracy for HER2+, triple-negative and HER2-/ER+ was 91.7%, 91.5%, and 89.6%, respectively, comparing with the biochemical defined breast cancer subtypes (Figure 1). This evidence concerns the gene ERBB2 and breast carcinoma.